Cherokee Insurance Co Sells 6,000 Shares of Astrazeneca Plc $AZN

Cherokee Insurance Co lowered its position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 50.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,000 shares of the company’s stock after selling 6,000 shares during the quarter. Cherokee Insurance Co’s holdings in Astrazeneca were worth $1,183,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Triumph Capital Management bought a new position in Astrazeneca during the third quarter worth about $25,000. MV Capital Management Inc. bought a new stake in Astrazeneca in the 4th quarter valued at about $26,000. Bangor Savings Bank grew its position in shares of Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares in the last quarter. Eagle Bay Advisors LLC bought a new position in shares of Astrazeneca during the fourth quarter worth approximately $30,000. Finally, YANKCOM Partnership bought a new position in shares of Astrazeneca during the fourth quarter worth approximately $31,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Get Astrazeneca alerts:

Astrazeneca Stock Down 0.1%

NYSE AZN opened at $194.96 on Friday. The business has a fifty day moving average price of $183.96 and a two-hundred day moving average price of $188.09. The stock has a market capitalization of $302.36 billion, a PE ratio of 29.27, a PEG ratio of 1.58 and a beta of 0.24. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Equities analysts expect that Astrazeneca Plc will post 10.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Bank of America reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday. Fourteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $205.33.

View Our Latest Report on Astrazeneca

Astrazeneca Profile

(Free Report)

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

Further Reading

• Five stocks we like better than Astrazeneca
• These Stocks Could Win as Wall Street Looks Beyond AI Software
• D.R. Horton Is Defying the Housing Gloom
• Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
• Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).

Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.